Dec. 20, 2016	Teijin Pharma, Amgen to Jointly Research and Develop New Therapy for Kidney Diseases
Nov. 04, 2016	Teijin Pharma Launches ReoGo®-J Device in Japan for Upper-limb Stroke Survivors
Aug. 10, 2016	Teijin Signs Agreement for Exclusive Development and Marketing Rights for Growth Hormone Deficiency Treatment
Jul. 27, 2016	Supplemental Application Filed for Somatuline® in Japan for Additional Indication of Neuroendocrine Tumors
May. 23, 2016	Teijin Pharma’s FEBURIC® (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia
Feb. 01, 2016	Teijin Pharma to Co-market New Anti-inflammatory Analgesic Patch Formulation
Jan. 29, 2016	Teijin Pharma to Start Rental Service for SLEEPMATE®10 Continuous Positive Airway Pressure Device

Page Top